Media ReleasesBionomics Limited

View All Bionomics Limited News


Bionomics Limited (ASX:BNO) BNC105 Data Presented at AACR Conference

BNC105 Data Presented at AACR Conference
 
Bionomics Limited (ASX:BNO; ADR:BMICY) today announced that its leading vascular disrupting agent (VDA), BNC105, would be the subject of two poster presentations at the prestigious annual American Association for Cancer Research (AACR) conference in Orlando, USA.
 
Data to be presented includes the VDA effects of BNC105 in two mouse models of renal cancer, including a model in which the cancer spreads to the lungs. BNC105 was shown to induce tumor blood vessel shutdown in both the primary tumor and the secondary lung cancer. BNC105 activity was shown to be comparable to that of the blockbuster drug Sutent which had worldwide sales of US$1.066 billion in 2010. Sutent is used in first line therapy of renal cancer.
 
A second poster describes the efficacy of BNC105 in mouse models of mesothelioma and lung cancer. In the mesothelioma tumor model the survival benefit of BNC105 treatment surpassed that of Alimta which is used in the treatment of human mesothelioma. The worldwide sales of Alimta in 2010 were US$2.208 billion.
 
BNC105 is currently in Phase II clinical trials in patients with renal cancer and in patients with mesothelioma. Bionomics anticipates reporting initial data from these trials in coming months. The preclinical data reported at AACR strongly supports these ongoing clinical trials.
 
Details of the scheduled poster presentations and their respective AACR abstracts are shown below.
 
Title: Evaluation of the anti-cancer effects of the tumor selective vascular disruption agent BNC105 in preclinical renal cancer models.
Authors: Tina C Lavranos (presenter), Annabell F Leske, Donna M Beaumont, Jelena Gasic and Gabriel Kremmidiotis
Session ID: Experimental and Molecule Therapeutics 4
Session: Sunday, April 3, 2011, 1:00 PM - 5:00 PM
Location: Exhibit Hall A4-C, Poster Section 28
Abstract Number: 662
Title: Anti-tumor activity of the vascular disruption agent BNC105 in models of mesothelioma and lung cancer.
Authors: Annabell F Leske (presenter), Donna M Beaumont, Tina C Lavranos, Jelena Gasic and Gabriel Kremmidiotis
Session ID: Experimental and Molecule Therapeutics 24
Session: Tuesday, April 5, 2011, 8:00 AM - 12:00 PM
Location: Exhibit Hall A4-C, Poster Section 27
Abstract Number: 3543
 
The posters can be found on the Bionomics website www.bionomics.com.au.
Download this document